疫苗制造商莫德纳（Moderna）周三盘中股价大跌5%，引发市场关注。这一跌幅与公司最新公告密切相关。
莫德纳宣布自愿撤回其针对50岁及以上成人的新冠病毒和流感联合疫苗（mRNA-1083）的生物制品许可证申请（BLA）。公司表示，将等待其实验性季节性流感疫苗mRNA-1010的后期试验疗效数据出炉后，再重新提交申请。莫德纳预计将在今年夏季公布mRNA-1010试验的中期数据。
这一决定可能影响了投资者对莫德纳近期产品管线的信心。值得注意的是，就在莫德纳宣布撤回申请的前一天，美国食品和药物管理局（FDA）表示，需要新的临床试验才能批准65岁以下健康人群每年接种新冠疫苗加强剂。这一系列事件加剧了市场对莫德纳未来收入前景的担忧，导致股价下跌。自今年年初以来，莫德纳股价已累计下跌超过30%，反映出投资者对公司面临的挑战持谨慎态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.